This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Statistical and Data Management Center (SDMC) for implementation of cross-protocol work in support of COVID-19 phase 3 efficacy trials. Due to the global COVID-19 pandemic, there is a significant need for a preventative SARS-CoV-2 vaccine. Addressing this gap, the HVTN has joined 4 other National Institute of Health (NIH) clinical trial networks to form the CoVPN, an enhanced network dedicated to developing globally effective vaccines for SARS-CoV-2. The CoVPN Statistical Center works across studies in protocol development for all CoVPN COVID vaccine trials and bears responsibility for ensuring harmonization of data and methods across trials. Thus, we have great insight into the comparability between trials with respect to endpoints and their measurement, baseline characteristics, and study populations. Additionally, the CoVPN Statistical Center brings its unique resources in terms of the background and expertise of our group: we are leaders in statistical methods in vaccine evaluation, especially for immune correlates assessment. Our work is informed by our long-standing and deep collaborative relationships with the clinical and lab groups in the CoVPN. In this study, the CoVPN Statistical Center will apply its world class laboratory, biostatistical and vaccine trial leadership expertise to assess COVID-19 vaccine-induced responses using cutting-edge cross-protocol statistical methods for evaluating vaccine efficacy, vaccine safety signals, incidence of infection and disease, and immunological correlates of protection.

Public Health Relevance

The outbreak of SARS-CoV-2 across the globe presents an unprecedented health risk to the world's population and requires intensive study of key gaps in our understanding of the immune response and what adaptations lead to protective immunity. In this study, the CoVPN will apply its world class laboratory, biostatistical and vaccine trial leadership expertise to assess this response using robust cross-protocol statistical methods for evaluating vaccine efficacy, vaccine safety signals, incidence of infection and disease, and immunological correlates of protection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
3UM1AI068635-14S3
Application #
10247368
Study Section
Program Officer
Renzullo, Philip O
Project Start
2020-11-13
Project End
2020-11-30
Budget Start
2020-11-13
Budget End
2020-11-30
Support Year
14
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Yu, Tingting; Wu, Lang; Gilbert, Peter (2018) New approaches for censored longitudinal data in joint modelling of longitudinal and survival data, with application to HIV vaccine studies. Lifetime Data Anal :
Yates, Nicole L; deCamp, Allan C; Korber, Bette T et al. (2018) HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. J Virol 92:
Fong, Youyi; Shen, Xiaoying; Ashley, Vicki C et al. (2018) Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. J Infect Dis 217:1280-1288
Fong, Youyi; Huang, Ying; Lemos, Maria P et al. (2018) Rank-based two-sample tests for paired data with missing values. Biostatistics 19:281-294
Reeves, Daniel B; Duke, Elizabeth R; Wagner, Thor A et al. (2018) A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat Commun 9:4811
Thiam-Diouf, Arame; Metch, Barbara; Sharpe, Cameron et al. (2018) Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention. Vaccine 36:1235-1242
Benkeser, David; Carone, Marco; Gilbert, Peter B (2018) Improved estimation of the cumulative incidence of rare outcomes. Stat Med 37:280-293
Lee, Unkyung; Sun, Yanqing; Scheike, Thomas H et al. (2018) Analysis of Generalized Semiparametric Regression Models for Cumulative Incidence Functions with Missing Covariates. Comput Stat Data Anal 122:59-79
Janes, Holly; Corey, Lawrence; Ramjee, Gita et al. (2018) Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. AIDS Res Hum Retroviruses 34:645-656
Dietrich, Janan J; Lazarus, Erica; Andrasik, Michele et al. (2018) Mobile Phone Questionnaires for Sexual Risk Data Collection Among Young Women in Soweto, South Africa. AIDS Behav 22:2312-2321

Showing the most recent 10 out of 167 publications